CRP and myocardial infarction: CANTOS was a secondary prevention study, which included 10,061participants with prior myocardial infarction and CRP values ≥2 mg/L.Along with standard therapy, patients were randomized to receive canakinumab(subcutaneously, in three available doses — 50 mg, 150 mg or 200 mg, every 3months), or placebo.